Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | PTPRB | P23467 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | PTEN | P60484 | 1/20 | 0.53 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524569 | 0.91 | FFAR1 (0.56) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL765727 | 0.90 | SMN1; SMN2 (0.58) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL11436467 | 0.89 | SMN1; SMN2 (0.56) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL14297620 | 0.89 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1MAPTSMN1; SMN2 | |
| Rubidium SCHEMBL11436472 | 0.89 | SMN1; SMN2 (0.56) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL11618279 | 0.88 | RAB9A (0.45) | CYSLTR2CYSLTR1RAB9AALDH1A1L3MBTL1 | |
| Phenyl Propionic Acid SCHEMBL28543455 | 0.87 | FFAR1 (0.51) | KEAP1FFAR1CYSLTR2CYSLTR1RAB9A | |
| SCHEMBL10290026 | 0.87 | CYSLTR2 (0.60) | CYSLTR2CYSLTR1MAPTSMN1; SMN2 | |
| SCHEMBL10290027 | 0.87 | CYSLTR2 (0.60) | CYSLTR2CYSLTR1MAPTSMN1; SMN2 | |
| SCHEMBL5914159 | 0.87 | KEAP1 (0.52) | KEAP1PTPRBCDC25ACDC25BPTEN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| CN-105233294-A | Phenylalkylcarboxylic acid delivery agent | EMISPHERE TECH INC | 2016-01-13 | — | — | CN | claimed |
| CN-101616583-A | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECH INC | 2009-12-30 | — | — | CN | claimed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3256451-B1 | IMIDAZOLYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11059792-B2 | Imidazolyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| CN-101616583-A | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECH INC | 2009-12-30 | — | — | CN | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059792-B2 | Imidazolyl tricyclic enones as antioxidant inflammation modulators | MPO, GPX4, NFE2L2 | KEAP1 66/4885PTPRB 2714/4885CDC25A 2593/4885 |
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | KEAP1 1202/4885PTPRB 3762/4885CDC25A 2378/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | KEAP1 1899/4885PTPRB 4686/4885CDC25A 3565/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KEAP1 1465/4885PTPRB 4560/4885CDC25A 1941/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | KEAP1 1202/4885PTPRB 3762/4885CDC25A 2378/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KEAP1 1465/4885PTPRB 4560/4885CDC25A 1941/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | KEAP1 1295/4885PTPRB 4468/4885CDC25A 3112/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | KEAP1 1295/4885PTPRB 4468/4885CDC25A 3112/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | KEAP1 1202/4885PTPRB 3762/4885CDC25A 2378/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KEAP1 1465/4885PTPRB 4560/4885CDC25A 1941/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | KEAP1 1202/4885PTPRB 3762/4885CDC25A 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.